Abstract: The present invention provides a liposome useful as a vaccine adjuvant. More specifically, the present invention provides a liposome which comprises a lipid bilayer comprising dimyristoylphosphatidylcholine and egg phosphatidylglycerol and a conjugated compound in which a low-molecular weight compound enhancing the physiological activity of TLR7 is bound to squalene via a linker, said conjugated compound being encapsulated in the lipid bilayer.
Abstract: The present application is directed to a cochleate composition including one or more cochleates and at least two antifungal compounds selected from amphotericin B, 5-flucytosine, fluconazole, ketoconazole, ravuconazole, albaconazole, itraconazole, posaconazole, isavuconazole and/or voriconazole. Methods of using the antifungal cochleate formulations are also disclosed.
Type:
Application
Filed:
July 12, 2017
Publication date:
April 23, 2020
Applicant:
Matinas BioPharma Nanotechnologies, Inc.
Inventors:
Raphael J. MANNINO, Ruying LU, Doug F. KLING
Abstract: Disclosed are targeted sub-50 nanometer nanoparticles suitable for delivering bioactive agents of interest, and related compositions, methods, and systems, which improve the manufacturing, stability, efficacy and other aspects of therapeutic nanoparticles.
Abstract: Fine dry particulate adenosine compositions suitable for use in topical formulations, as well as methods of making the same, are provided. In the dry particulate adenosine composition, the adenosine active agent is associated with the particles, e.g., via entrapment in the pores of the particles and/or ionic binding and/or non-covalent binding to the surface of the particles and/or loosely associated with the particles. Also provided are topical formulations which include the dry particulate adenosine compositions of the invention, and methods of using the same.
Abstract: Solid formulations comprising a compound having formula (I) or a pharmaceutically acceptable salt thereof, and their use in the treatment of neurologic disorders (such as pantothenate kinase-associated neurodegeneration), are provided.
Abstract: Disclosed herein is anticancer composition comprising an anti-cancer agent and poly(lactic-co-glycolic acid) (PLGA) carrier thereof. Further disclosed herein is a method for treating a breast disorder in a subject in need thereof, comprising administering to the breast of a subject via an intraductal injection an effective amount of a composition comprising a therapeutic agent and a PLGA carrier thereof. In some aspects the carrier is a microsphere.
Abstract: Provided are solid oral/per os formulations that include a single cannabinoid, combination of cannabinoids, cannabis extract and combination of cannabis plant constituents. Also provided are methods of making the formulations, as well as therapeutic applications in the treatment and alleviation of various human disorders and/or conditions.
Abstract: The invention pertains to dispersible tablets comprising as active ingredient N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, methanesulfonate salt, processes for preparing the same, and processes for using the same.
Type:
Application
Filed:
June 29, 2018
Publication date:
April 23, 2020
Inventors:
Nikos KARANIKOLOPOULOS, Paul Anthony GOULDING
Abstract: In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
Abstract: The present disclosure discloses a pH-sensitive starch-based microcapsule encapsulating a fat-soluble substance and a preparation method thereof, and belongs to the field of preparation of starch-based hydrogel microcapsules. The method of the present disclosure comprises performing acid hydrolysis on starch to obtain acid-hydrolyzed carboxymethyl starch, mixing the acid-hydrolyzed carboxymethyl starch with xanthan gum to obtain a compounded solution of starch and colloid, adding an emulsifier and the fat-soluble substance, emulsifying to obtain an emulsion, and drying to obtain the microcapsule.
Type:
Application
Filed:
December 19, 2019
Publication date:
April 23, 2020
Inventors:
Yan HONG, Min JIANG, Zhengbiao GU, Li CHENG, Zhaofeng LI, Caiming LI
Abstract: The invention discloses a composition comprising surface modified iron oxide nanoparticles with citric acid modified cyclodextrin with a hydrodynamic diameter of less than 10 nm and a hydrophobic molecule. The composition finds use in targeted delivery of a hydrophobic drug and as contrast agent in imaging applications.
Type:
Application
Filed:
October 25, 2019
Publication date:
April 23, 2020
Applicant:
COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
Abstract: A patch comprising: a backing layer; and an adhesive layer, wherein the adhesive layer contains a mixture of a pharmaceutically acceptable acid addition salt of ropinirole and potassium hydrogen carbonate, and the mixture contains at least one selected from the group consisting of ropinirole and pharmaceutically acceptable acid addition salts thereof and potassium hydrogen carbonate.
Abstract: An external patch that contains rupatadine as a second-generation antihistamine, has excellent plaster physical properties, good adhesion to applied skin, and good transdermal absorption of rupatadine as an active ingredient is provided. The external patch containing rupatadine uses an acrylic adhesive as an adhesive base. Specifically, the external patch containing rupatadine uses an acrylic adhesive as an adhesive base and further contains an organic acid having 2 to 7 carbon atoms as a solubilizer, a fatty acid ester as a softener, and/or a surfactant.
Type:
Application
Filed:
April 18, 2018
Publication date:
April 23, 2020
Applicants:
TEIKOKU SEIYAKU CO., LTD., J.URIACH Y COMPANIA S.A.
Abstract: A patch comprises a backing layer and an adhesive layer, wherein the adhesive layer contains at least one selected from the group consisting of butorphanol and pharmaceutically acceptable salts thereof, and contains a rubber-based adhesive base and a silicone-based adhesive base, and a mass ratio of the rubber-based adhesive base to the silicone-based adhesive base (the mass of the rubber-based adhesive base:the mass of silicone-based adhesive base) in the adhesive layer is 9.5:0.5 to 1.9:8.1.
Abstract: A flexible, transparent gel patch product contains a clear cannabinoid-infused hydrogel material in a gel-like phase. The gel patch product is comprised of several layers including a gel layer, removable tab and release liner. The removable tab provides a graspable surface to allow for the removal of the release liner from the gel patch and to facilitate handling of the gel patch during application to the skin. The tab may be comprised of a flat, double-coated paper or other suitable material, or a flexible, V-shaped member, and is removable by peeling after the gel patch is applied. The gel patch includes a transparent cover and a grid pattern may be printed on the backing layer to permit visualization of the underlying skin and measurement of any injury or wounds, for example.
Abstract: Provided herein are compositions, systems, and methods for causing weight loss and treating and/or preventing a disease or condition, such as obesity, diabetes, and cancer, with an agent or procedure that inhibits the TMA/FMO3/TMAO pathway in a subject.
Abstract: The present invention provides compositions comprising a combination of cannabidiol (CBD) or a derivative thereof, and hyaluronic acid or a salt thereof; a phospholipid, and optionally a carrier, methods of using the compositions for treating inflammatory joint diseases, or pain or inflammation associated with such diseases, and methods for their preparation.
Abstract: Compounds, compositions, and methods for treatment of, or prophylaxis against, inflammation and/or oxidative stress are disclosed.
Type:
Application
Filed:
April 14, 2018
Publication date:
April 23, 2020
Inventors:
Guy M. MILLER, Jeffery K. TRIMMER, William D. SHRADER, Andrew W. HINMAN, Charles R. HOLST, Joey C. LATHAM, Joel J. BRUEGGER, Kevin P. MCCUSKER, Gozde ULAS, Dana DAVIS, Amanda H. KAHN-KIRBY, Edgar P. LEE, Stephanie A. MALONE, Steven J. RICHARDS, Matthew B. KLEIN
Abstract: The present invention relates to hydroxynorketamine for the use in the treatment of depression. In particular, the present invention concerns hydroxynorketamine for use in the treatment of depression, wherein hydroxynorketamine is administered in form of at least one prodrug, and wherein the at least one prodrug is orally administered in a modified-release dosage form. The prodrug is selected from (S)-Ketamine, (R)-Ketamine, (R,S)-Ketamine, (S)-Norketamine, (R)-Norketamine, (R,S)-Norketamine, (S)-Hydroxyketamine, (R)-Hydroxyketamine, (R,S)-Hydroxyketamine.
Abstract: The present invention relates to an agent for use in selectively killing one or more senescent cells, wherein said agent is selected from the following: a cardiac glycoside or alglycone, a focal adhesion kinase (FAK) inhibitor, an HMG-CoA reductase inhibitor, JFD00244, Cyclosporine, Tyrphostin AG879, Cantharidin, Diphenyleneiodonium chloride, Rottlerin, 2,3-Dimethoxy-1,4-naphthoquinone, LY-367,265, Rotenone, Idarubicin, Dequalinium chloride, Vincristine, Nitazoxanide, Nitrofurazone, Temsirolimus, Eltrombopag, Adapalene, Azacyclonol, Enoxacin and Raltegravir, and pharmaceutically acceptable salts thereof. Another aspect relates to compounds for use in treating or preventing a senescence-associated disease or disorder, and methods relating thereto.
Type:
Application
Filed:
May 25, 2018
Publication date:
April 23, 2020
Inventors:
Jesus GIL, Ana GUERRERO, Nicolas HARRANZ
Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
Type:
Application
Filed:
December 19, 2019
Publication date:
April 23, 2020
Inventors:
Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
Abstract: A method of forming an implant in a tissue can include: providing an injectable liquid composition comprising one or more precursors of a crosslinkable composition; injecting the injectable composition into the tissue at the rate of about 10-12000 injections per minute and/or at an amount of 1.0E-02 ml to 1.0E-16 ml per injection; and crosslinking the one or more precursors of the crosslinkable composition so as to form a crosslinked composition.
Abstract: Ketogenic compositions including a plurality of beta-hydroxybutyrate (BHB) salts and beta-hydroxybutyric acid are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB composition is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes beta-hydroxybutyric acid and a plurality of BHB salts selected from sodium, potassium, calcium, and magnesium. The BHB composition may include transition metal cations (e.g., zinc or iron), one or more BHB-amino acid salts, a short-, medium-, or long chain fatty acid source, vitamin D3, flavorant, or other excipient.
Abstract: The present invention provides a method of administering magnesium threonate to a subject in need of supplementing magnesium. At least a portion of magnesium (Mg) and threonate (T) is present in a salt form of MgT2. The method may comprise administration of magnesium threonate at two different time points per day. The method may comprise administering, at a first time point, a first oral dosage form comprising magnesium threonate. The method may comprise administering, at a second time point, a combination of the first oral dosage form and a second oral dosage form comprising magnesium threonate. The first and second oral dosage forms may exhibit different dissolution profiles in a dissolution medium.
Abstract: There is provided a convenient new treatment of Parkinson disease by a frequent administration of optimal levodopa doses mimicking a continuous intravenous or infusion treatment, thus mitigating motor complications; and a new carbidopa/levodopa pharmaceutical unit form providing said new treatment.
Type:
Application
Filed:
December 18, 2019
Publication date:
April 23, 2020
Applicant:
AVION PHARMACEUTICALS, LLC
Inventors:
Thomas N. CHASE, Kathleen E. CLARENCE-SMITH
Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating a muscle disease, comprising, as an active ingredient, azelaic acid or a pharmaceutically acceptable salt thereof. In muscle cells, the azelaic acid according to the present disclosure can increase expression of proteins associated with muscle protein synthesis and muscle mass increase and can inhibit expression of enzymes involved in muscle protein degradation; and therefore the azelaic acid can exhibit a muscle strength-enhancing effect through muscle differentiation, muscle regeneration, and muscle mass increase in a muscle disease caused by muscle function decline, muscle wasting, or muscle degeneration. In addition, the azelaic acid can inhibit muscle decrease. Accordingly, the azelaic acid can be used for preventing or treating a muscle disease, differentiating muscles, regenerating muscles and enhancing muscles, or for increasing muscle mass, promoting muscle production, or improving muscle function.
Type:
Application
Filed:
October 16, 2019
Publication date:
April 23, 2020
Applicant:
INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
Abstract: The present invention relates to a pharmaceutical composition, containing sarpogrelate or a pharmaceutically acceptable salt thereof as an active ingredient, for preventing, alleviating, or treating sensorineural hearing loss. The sarporgrelate according to the present invention protects against hearing loss caused by noise through the suppression of auditory cell apoptosis and the expression increase of antioxidant enzyme in auditory cells, and thus can be advantageously used in the prevention and alleviation of sensorineural hearing loss.
Type:
Application
Filed:
April 10, 2018
Publication date:
April 23, 2020
Inventors:
Yun-Hoon CHOUNG, Young Sun KIM, Young-Joon PARK
Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
Type:
Application
Filed:
December 13, 2019
Publication date:
April 23, 2020
Inventors:
Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
Abstract: Certain embodiments of the invention pertain to a method of treating an infection in a subject caused by an infectious agent other than Escherichia coli, the method comprising administering to the subject arsinothricin or a salt thereof. The infectious agent other than E. coli can be a bacterium, protozoan, helminth, archaebacterium, or a fungus. In preferred embodiments, the infectious agent is Mycobacterium tuberculosis, Mycobacterium brevis, or Enterobacter cloacae. The invention also pertains to a method of treating an infection in a subject caused by an infectious agent, comprising administering to the subject arsinothricin or a salt thereof in combination with an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. In certain such embodiments, the infectious agent expresses phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase.
Type:
Application
Filed:
October 17, 2018
Publication date:
April 23, 2020
Applicant:
The Florida International University Board of Trustees
Abstract: The disclosed subject matter provides N-substituted hydroxylamine derivative compounds, pharmaceutical compositions and kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure.
Type:
Application
Filed:
December 23, 2019
Publication date:
April 23, 2020
Inventors:
Vincent Jacob Kalish, Frederick Arthur Brookfield, Stephen Martin Courtney, Lisa Marie Frost, John P. Toscano
Abstract: The present invention relates to a pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy including baicalein as an active ingredient. Baicalein is capable of regulating thymic stromal lymphopoietin-mediated signal transduction. The pharmaceutical composition of the present invention can effectively suppress inflammatory responses of allergic or asthmatic diseases due to the presence of baicalein extracted from Scutellariae Radix that regulates TSLP-mediated intracellular signal transduction to inhibit intracellular phosphorylation of STATS and inhibit the binding of TSLP to TSLPR. In addition, the pharmaceutical composition of the present invention may further include one or more compounds having synergistic effects with baicalein. In this case, the pharmaceutical composition can more effectively suppress inflammatory responses of allergic diseases such as asthma or atopy.
Type:
Application
Filed:
January 4, 2018
Publication date:
April 23, 2020
Applicant:
Korea University Research and Business Foundation, Sejong Campus
Inventors:
Ki Yong LEE, Young Ho JEON, Youngjoo BYUN, Kiho LEE, Yong Woo JUNG
Abstract: Provided herein is a pharmaceutical composition comprising an isoflavonoid derivative and a cyclodextrin. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions. In specific instances, provided herein are intravenous compositions and therapies.
Abstract: Presented herein are methods for treating bile acid diarrhea, short bowel syndrome (SBS), and cholecystectomy-associated diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. In particular embodiments, infants, and juveniles with SBS are treated with an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
Type:
Application
Filed:
May 31, 2018
Publication date:
April 23, 2020
Inventors:
Lisa A. Conte, Pravin R. Chaturvedi, Charles Conte
Abstract: This disclosures relates to new compositions and methods for making cannabinoid formulations. In one embodiment, this disclosure provides water soluble compositions comprising a first purified cannabinoid and Vitamin E TPGS. In one embodiment, the disclosure herein comprises a method of making powders comprising heatings material to a first temperature and a second temperature.
Abstract: Formulations for topical use based on vitamin E or an ester thereof for use in removing, reducing or inhibiting a bacterial and/or fungal biofilm, are disclosed. The ester of vitamin E is an ester with a carboxylic acid of formula R—COOH, in which R is an alkyl radical having from 1 to 19 carbon atoms, or an alkenyl or alkynyl having from 2 to 19 carbon atoms.
Abstract: The present invention is drawn to methods for effecting weight loss, e.g.. in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se.
Abstract: The present invention relates to stable therapeutic compositions of pharmaceutical grade acids and pH buffering agents. The present invention also is directed to methods of treatment for mitochondrial disorders, metabolic conditions, diabetic conditions, and cardiovascular conditions, by administration of compositions of the present disclosure.
Type:
Application
Filed:
October 28, 2019
Publication date:
April 23, 2020
Applicant:
Reven, LLC
Inventors:
James Ervin, Hendrik J. Van Wyk, Brian D. Denomme, Mariette L. Van Wyk, Peter Pacult, Michael A. Volk
Abstract: Methods for inhibiting cell growth, inhibiting DNA polymerase activity, and inhibiting DNA replication and repair are provided. In a method of inhibiting cell growth, a cell, such as a cancer cell, is contacted with zelpolib or a derivative or pharmaceutically acceptable salt thereof. The cell growth can be inhibited in vivo, and in certain embodiments, the cell growth is inhibited in vitro. In a method for inhibiting DNA polymerase activity, a DNA polymerase is contacted with zelpolib or a derivative or pharmaceutically acceptable salt thereof. In certain embodiments, the DNA polymerase is Pol ?. In a method for inhibiting DNA replication and repair, a cell, such as a cancer cell, is contacted with zelpolib or a derivative or pharmaceutically acceptable salt thereof. The DNA replication and repair can be inhibited in vivo, and in certain embodiments, the DNA replication and repair is inhibited in vitro.
Abstract: Activating transcription factor 6 (ATF6) is involved in cystic fibrosis transmembrane conductance regulator (CFTR) repression and understanding this inhibitory mechanism is of great interest to develop a therapeutic approach based on UPR regulation. Using site-1 protease (S1P) inhibitor (e.g. PF-429242) the inventors showed that both membrane localization and function of F508del-CFTR are partially restored. Accordingly, the present invention relates to a method of treating a disease associated with reduced CFTR function in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a S1P inhibitor.
Type:
Application
Filed:
April 20, 2018
Publication date:
April 23, 2020
Inventors:
PASCAL TROUVE, CLAUDE FEREC, MATHIEU KERBIRIOU, FLORENTIN HUGUET
Abstract: Topical formulations comprising soft glycopyrrolates are useful for treating excessive sweating conditions in subjects, such as humans suffering from hyperhidrosis. Preferably, at least one soft anticholinergic agent is provided in an effective amount or concentration in an anhydrous formulation that can inhibit excessive perspiration resulting from a condition such as hyperhidrosis.
Type:
Application
Filed:
December 5, 2019
Publication date:
April 23, 2020
Inventors:
Nicholas S. BODOR, John J. KOLENG, David ANGULO
Abstract: Methods of treating sepsis induced acute brain dysfunction (SiBD), comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. Methods of reducing sepsis mortality, comprising administering a synaptic vesicle 2a and/or 2b binding chemical entity to a subject with sepsis. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is a synaptic vesicle 2a and/or 2b modulator such as agonist, partial agonist, antagonist or partial antagonist. In some embodiments the synaptic vesicle 2a and/or 2b binding chemical entity is levetiracetam or a derivative or analogue of levetiracetam. In some embodiments the synaptic vesicle 2a binding chemical entity is levetiracetam.
Type:
Application
Filed:
May 19, 2017
Publication date:
April 23, 2020
Inventors:
Tarek SHARSHAR, Fabrice CHRETIEN, Aurelien MAZERAUD, Fernando Augusto BOZZA
Abstract: Disclosed is a composition and method for preventing, ameliorating or treating an EGFR-mutant non-small cell lung cancer including a c-Jun N-terminal kinase (JNK) activator as an active ingredient. The composition significantly reduces the level of EGFR in EGFR-mutant non-small cell lung cancer cells, inducing apoptosis. Therefore, the composition is suitable for preventing, ameliorating or treating non-small cell lung cancers in subjects in need thereof. Particularly, the composition is effective in treating and preventing non-small cell lung cancers, which are difficult to effectively treat and prevent with gefitinib or erlotinib. Also disclosed is a composition and method for inhibiting the resistance of a non-small cell lung cancer to an EGFR tyrosine kinase inhibitor including a c-Jun N-terminal kinase (JNK) activator as an active ingredient. The inhibitory composition effectively overcomes resistance to EGFR tyrosine kinase inhibitors.
Type:
Application
Filed:
February 13, 2019
Publication date:
April 23, 2020
Applicants:
THE ASAN FOUNDATION, University of Ulsan Foundation For Industry Cooperation
Inventors:
Jaekyoung SON, Jin Kyung RHO, Jae Cheol LEE
Abstract: The present application discloses chemical compositions and methods for enhancing the transdermal permeation of therapeutic agents through skin. The chemical compositions and methods of the invention can include combinations of a first fatty acid having about 14 or more carbon atoms and a second fatty acid having about 10 or less carbon atoms. These compositions are useful for the delivery of therapeutic agents, in particular hard to deliver drugs such as those that have fused rings, including ondansetron, and large drugs such as peptides. The compositions of the invention can be formulated as transdermal gels, lotions, creams, transdermal patches, sprays or mists.
Abstract: The present invention relates to substituted indoline derivatives, methods to prevent or treat dengue viral infections by using said compounds and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
Abstract: Provided is a pharmaceutical composition which contains pemafibrate, a salt thereof or a solvate thereof and one or more selected from the group consisting of a metal oxide, a dihydric alcohol, an ester species and a silicic acid compound and which has excellent storage stability. The pharmaceutical composition includes the following components (A) and (B): (A) pemafibrate, a salt thereof or a solvate thereof; and (B) one or more selected from the group consisting of the following components (B-1) to (B-4): (B-1) a metal oxide; (B-2) a dihydric alcohol; (B-3) an ester species; and (B-4) a silicic acid compound, with component (A) and component (B) being substantially in non-contact with each other.
Abstract: Provided is a novel technique for improving storage stability of a pharmaceutical composition containing pemafibrate, a salt thereof or a solvate thereof and a cellulose species. A pharmaceutical preparation obtained by storing a pharmaceutical composition containing the following components (A) and (B) in a tight package: (A) pemafibrate, a salt thereof or a solvate thereof; and (B) a cellulose species.